14. The FAO and WHO Joint Secretaries of JECFA summarized the results of the forty-seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA).
15. Thirteen veterinary drugs were evaluated. Acceptable Daily Intakes (ADIs) and Maximum Residue Limits (MRLs) were allocated/confirmed for clenbuterol, abamectin, moxidectin, chlortetracycline, oxytetracycline, tetracycline, neomycin, spiramycin, cypermethrin, a-cypermethrin, and tilmicosin. MRLs for cypermethrin and a-cypermethrin, and for tilmicosin in sheep milk, were made temporary pending further information. A temporary ADI and temporary MRLs were established for thiamphenicol. The Expert Committee could recommend neither an ADI nor MRLs for xylazine.
16. A working paper on procedures for assessing the effects of antimicrobial veterinary drug residues in food on the human intestinal microflora was reviewed. This paper incorporated comments made by a large number of scientists who had been given an opportunity to review an earlier draft that was considered at the forty-fifth meeting. The Committee emphasized that it was not committed to any one procedure and encouraged the validation of present procedures and the development of better procedures for assessing microbiological risk.
17. Two errors in the summary report were identified. One was that clenbuterol and xylazine should not be as b-adrenoceptor blocking agents, since Clenbuterol was a b-adrenoceptor agonist and xylazine was a a2 adrenoceptor agonist. The other was that an MRL of 100 µg/kg for fish muscle for oxytetracycline should have been included. These corrections will appear in the final report to be published in the WHO Technical Report Series.
